A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

NCT02963766 · Completed

Last updated 2026-05-28

This clinical trial tested the medication dulaglutide in children and adolescents aged 10 to 17 with type 2 diabetes to see how it affects their blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 154 people

Who can join Ages 10–17 · all sexes

Timeline Started 2016-12 · est. completion 2022-01

Where 61 sites · Brazil, France, Germany, Hungary, India, Mexico, Puerto Rico, Saudi Arabia, Turkey (Türkiye), United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02963766 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02963766 ↗